

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

SAMSUNG BIOEPIS CO. LTD,
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Case IPR2023-00884
Patent No. 11,253,572

EXPERT DECLARATION OF RICHARD MANNING. PH.D.

CONFIDENTIAL MATERIAL - SUBJECT TO PROTECTIVE ORDER

Table of Contents

1.	Introduction	1
1.1.	Qualifications.....	1
1.2.	Scope of work.....	3
1.3.	Framework for commercial success	4
2.	U.S. Patent No. 11,253,572.....	7
3.	Commercial Success	10
3.1.	U.S. Eylea sales	11
3.2.	Eylea’s share of anti-VEGF sales.....	11
3.2.1.	Data sources	12
3.2.2.	Eylea’s historic sales share as an indicator of commercial success	12
3.2.3.	Eylea’s sales growth trends as an indicator of commercial success	17
3.2.4.	Eylea status as physicians’ most used treatment.....	21
4.	Dosing Regimen is An Important Driver of Demand for Eylea	23
4.1.	Eylea’s patented dosing regimen addressed an unmet need for longer dosing intervals	24
4.2.	Eylea’s patented dosing regimen, including the 8-week fixed dosing interval in the maintenance phase, is a key differentiating factor	27
4.3.	The most common dosing interval for Eylea is approximately eight weeks	29

Table of Attachments

<u>Section A</u>	<u>Expert Materials</u>
Attachment A-1	Curriculum Vitae of Richard Manning, Ph.D
Attachment A-2	Expert Testimony of Richard Manning, Ph.D
<u>Section B</u>	<u>FDA Labels</u>
Attachment B-1	Dosing Directions on FDA Labels
<u>Section C</u>	<u>Sales Share Summaries</u>
Attachment C-1	Sales Share Summary - All Indications
Attachment C-2	Sales Share Summary - DME
Attachment C-3	Sales Share Summary - DR without DME
Attachment C-4	Sales Share Summary - Wet AMD
Attachment C-5	Sales Share Summary - RVO
Attachment C-6	Eylea's Sales Share Across Different Data Sources - All Indications
Attachment C-7	Eylea's Sales Share Across Different Data Sources - DME
Attachment C-8	Eylea's Sales Share Across Different Data Sources - DR without DME
Attachment C-9	Eylea's Sales Share Across Different Data Sources - Wet AMD
Attachment C-10	Eylea's Sales Share Across Different Data Sources - RVO
Attachment C-11	Percentage Point Change in Total Sales Share Since Eylea Launch – ATU Data

CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

Attachment C-12 Percentage Point Change in Total Sales Share Since Eylea Launch – Medicare Part B Data

Section D P&L and ASP Analyses

Attachment D-1 Eylea Profit and Loss Data (Actuals, 2011–2021)

Attachment D-2 Eylea Volume and Revenue Performance (2011–2021)

Section E Other Analyses

Attachment E-1 Most Prescribed Treatment Options (2012–2020)

Attachment E-2 Volume of Medicare Patients by Brand – Medicare Part B

Attachment E-3 Summary of Most Common Dosing Intervals for DME
According to ATU Surveys

Attachment E-4 Summary of Most Common Dosing Intervals for Wet AMD
According to ATU Surveys

Attachment E-5 Medicare Part B Patients Treated, By Year and Treatment
(2012 – 2021)

Section X Data

Attachment X-1 Vestrum Sales Share Data by Indication

Attachment X-2 ATU Sales Share Data by Indication

Attachment X-3 Medicare Part B Sales Shares Data (2012–2021)

Attachment X-4 HCPCS Code to Brand Name Mapping

Attachment X-5 Summary of ATU Survey Reports: Dosing Frequencies by
Indication and Treatment

Section Y STATA Log Files

CONFIDENTIAL MATERIAL – SUBJECT TO PROTECTIVE ORDER

- Attachment Y-1 Log File for Importing 2021 CMS Medicare Part B Data
- Attachment Y-2 Log File for Appending Data into Final Complete Dataset
- Attachment Y-3 Log File for Attachment X-3
- Attachment Y-4 Log File for Attachment E-1

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.